Fromkin Andrew J. 4

4 · Immunovant, Inc. · Filed Apr 9, 2026

AI-generated summary of this filing

Updated Apr 9, 2026

Immunovant (IMVT) Director Andrew Fromkin Receives RSU & Option Awards

What Happened

Andrew J. Fromkin, a director of Immunovant, was granted equity awards on April 7, 2026: 13,880 restricted stock units (RSUs) and 7,061 option-type awards (reported as a derivative). Both grants were reported at $0.00 (no cash paid).
These awards are compensation grants, not open-market purchases or sales, so they represent expected future stock delivery if vesting conditions are met rather than an immediate change in share ownership.

Key Details

Transaction date: 2026-04-07; Form 4 filed 2026-04-09 (timely within the required reporting window).
Reported price: $0.00 for both grants (typical for awards/RSUs).
Vesting: Both the RSUs and the shares underlying the options vest in full on April 1, 2027, contingent on Fromkin’s continuous service through that date.
Footnotes: F1 explains each RSU equals a contingent right to one share and may be deferred upon vesting under Rule 409A; F2 confirms the second item are options granted under the company’s equity plan.
Shares owned after transaction: not specified in the provided filing excerpt.
No 10b5-1 plan, tax-withholding sale, or late-filing flag disclosed in this report.

Context

RSUs and option grants are common director compensation and do not necessarily indicate the director bought or sold shares; they create future potential ownership if vesting conditions are met.
Because these awards vest in the future, there was no immediate sale or exercise (no cashless exercise or proceeds reported). Retail investors often view purchases as stronger signals than grants, which are routine compensation.

Form 4

Period: 2026-04-07

Director

Transactions

Award
Common Stock
[F1]
2026-04-07+13,880→ 99,732 total
Award
Stock Option (right to buy)
[F2]
2026-04-07+7,061→ 7,061 total
Exercise: $24.61Exp: 2036-04-07→ Common Stock (7,061 underlying)

Footnotes (2)

[F1]These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
[F2]These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.

Signature

/s/ Tiago Girao, attorney-in-fact for Andrew J. Fromkin|2026-04-09

1 file